Cargando…
Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
BACKGROUND: Approximately 20-25% of ovarian cancers are attributable to germline or somatic BRCA1/2 mutations, resulting in defects in the homologous recombination pathway. Inactivation of these genes can also be mediated by epigenetic changes, e.g., hypermethylation of CpG islands in the promoter r...
Autores principales: | Prieske, Katharina, Prieske, Stefan, Joosse, Simon A., Trillsch, Fabian, Grimm, Donata, Burandt, Eike, Mahner, Sven, Schmalfeldt, Barbara, Milde-Langosch, Karin, Oliveira-Ferrer, Leticia, Woelber, Linn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669950/ https://www.ncbi.nlm.nih.gov/pubmed/29137324 http://dx.doi.org/10.18632/oncotarget.20945 |
Ejemplares similares
-
E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer
por: Trillsch, Fabian, et al.
Publicado: (2016) -
VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
por: Kuerti, Sascha, et al.
Publicado: (2017) -
BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
por: Elazezy, Maha, et al.
Publicado: (2021) -
Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
por: Mahner, Sven, et al.
Publicado: (2015) -
VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients
por: Ding, Yi, et al.
Publicado: (2022)